Ignite Creation Date:
2024-05-06 @ 6:30 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05687266
Status:
RECRUITING
Last Update Posted:
2024-07-09
First Post:
2022-12-28
Brief Title:
Phase III Open-label First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Sponsor:
Organization:
AstraZeneca